All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Ruben A. MesaDuring the 14th International Congress of Myeloproliferative Neoplasms, the MPN Hub was pleased to speak to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, How do symptoms inform treatment decisions in myeloproliferative neoplasms (MPN)?
How do symptoms inform treatment decisions in MPN?
Mesa opens by remarking on the range of different symptoms patients with MPN may experience and the effects these differing symptoms may have on disease presentation and progression. Mesa comments on symptoms as a marker of health-related quality of life and their subsequent use in informing the decision to initiate or alter treatment.
Mesa concludes by reiterating the importance of improving symptoms and quality of life as a cornerstone of treatment.